Role of 18F-FDG PET/CT in Gastric Cancer
1 other identifier
observational
50
0 countries
N/A
Brief Summary
The objective of the study is to assess the value of PET/CT in diagnosis, staging, response evaluation, and relapse monitoring of gastric cancer.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Jan 2023
Shorter than P25 for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2023
CompletedFirst Submitted
Initial submission to the registry
January 8, 2023
CompletedFirst Posted
Study publicly available on registry
January 18, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
January 1, 2024
CompletedJanuary 18, 2023
January 1, 2023
11 months
January 8, 2023
January 8, 2023
Conditions
Outcome Measures
Primary Outcomes (1)
comparison of pet -ct finding with ct finding
The 18F-FDG PET/CT scan is visually estimated in the patients included in the study and quantitatively assessed by estimation of standardized uptake value(suv max). Statistical analysis of the included quantitative data.
base line
Interventions
assessment of added value of pet -ct in patients with gastric cancer and how patient get benefit from this finding
Eligibility Criteria
patient diagnosed by pathology as gastric cancer
You may qualify if:
- patients diagnosed as GC on surgically resected specimens;
- Patients with gastric and extragastric metastasis.
- patients with gastric cancer either operated or not.
You may not qualify if:
- Patients with second malignancy.
- Patient without proven pathology of cancer stomach.
- Severely ill patient (patient with disturbed conscious level, or couldn't lay supine during the imaging).
- uncontrolled diabetic patient with blood glucose level more than 200mg\\dl.
- pregnant women
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Sohag Universitylead
Related Publications (3)
Tang L, Wang XJ, Baba H, Giganti F. Gastric cancer and image-derived quantitative parameters: Part 2-a critical review of DCE-MRI and 18F-FDG PET/CT findings. Eur Radiol. 2020 Jan;30(1):247-260. doi: 10.1007/s00330-019-06370-x. Epub 2019 Aug 7.
PMID: 31392480BACKGROUNDSaka M, Katai H, Fukagawa T, Nijjar R, Sano T. Recurrence in early gastric cancer with lymph node metastasis. Gastric Cancer. 2008;11(4):214-8. doi: 10.1007/s10120-008-0485-4. Epub 2009 Jan 8.
PMID: 19132483BACKGROUNDLiu Q, Li J, Xin B, Sun Y, Feng D, Fulham MJ, Wang X, Song S. 18F-FDG PET/CT Radiomics for Preoperative Prediction of Lymph Node Metastases and Nodal Staging in Gastric Cancer. Front Oncol. 2021 Sep 13;11:723345. doi: 10.3389/fonc.2021.723345. eCollection 2021.
PMID: 34589429RESULT
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
wafaa elmaghraby, ass prof
Sohag University
- STUDY DIRECTOR
mohamed soliman, prof
Sohag University
Central Study Contacts
waleed diab, ass prof
CONTACT
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- assisstant lecturer
Study Record Dates
First Submitted
January 8, 2023
First Posted
January 18, 2023
Study Start
January 1, 2023
Primary Completion
December 1, 2023
Study Completion
January 1, 2024
Last Updated
January 18, 2023
Record last verified: 2023-01
Data Sharing
- IPD Sharing
- Will not share